billHR8376Event Monday, April 20, 2026Analyzed

Concurrent Care for Comfort Act

Bullish

Summary

HR8376 (Concurrent Care for Comfort Act) is an early-stage bill that clarifies Medicare coverage and separate payment for palliative dialysis services furnished concurrently with hospice care. It has been referred to two committees and has only one cosponsor, indicating low legislative momentum. The bill's direct market impact is minimal, as it affects a narrow patient population and does not authorize new funding.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR8376 is an early-stage bill with low momentum (1 sponsor, 1 cosponsor, no committee action since referral).
  • 2.The bill clarifies Medicare coverage for palliative dialysis during hospice, creating a small incremental revenue opportunity for dialysis providers.
  • 3.No new funding is authorized; the impact is limited to a narrow patient population, making the market effect minimal.

Market Implications

The bill's direct market implications are minimal. Dialysis providers $DVA and $FMS may see a slight uptick in utilization from hospice patients, but this represents less than 0.1% of their annual revenue. No other sectors or tickers are materially affected. Investors should monitor committee markups or a Senate companion bill for signs of increased momentum, but currently this is a non-event for markets.

Full Analysis

On April 20, 2026, Representative Mike Kelly (R-PA) introduced HR8376, the Concurrent Care for Comfort Act, which amends the Social Security Act to clarify that Medicare covers palliative dialysis services for hospice patients and that such services are paid separately from the hospice bundled payment. The bill was referred to the House Ways and Means and Energy and Commerce Committees. As of June 1, 2026, no further action has occurred; the bill remains in early legislative stages.

The bill does not authorize or appropriate any new funding. It modifies existing Medicare payment rules to allow separate billing for dialysis during hospice, which previously was ambiguous. The Congressional Budget Office would likely score this as a small increase in Medicare spending due to increased utilization, but no dollar figure is specified in the bill text.

The primary beneficiaries are dialysis providers DaVita ($DVA) and Fresenius Medical Care ($FMS), which operate the majority of US dialysis clinics. The bill removes a coverage barrier, potentially allowing more hospice patients to receive dialysis. However, the number of Medicare hospice patients who would elect dialysis is small—estimated at a few thousand annually—so the revenue impact is marginal relative to these companies' multibillion-dollar revenues.

No real market data on stock price movements is provided, but structurally, $DVA and $FMS are the only publicly traded pure-play dialysis providers. The bill's low legislative momentum (single sponsor, one cosponsor, early referral) suggests passage is uncertain and unlikely in the near term.

The timeline for this bill is extended: it must pass both House committees, the full House, the Senate, and be signed by the President. Given the 119th Congress is in its second session, the window for passage is narrowing. No companion bill has been introduced in the Senate.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$DVA▲ Bullish
Est. $5.0M$20.0M revenue impact

What the bill does

Clarifies Medicare coverage and separate payment for palliative dialysis services furnished concurrently with hospice care to eligible individuals.

Who must act

Renal dialysis facilities and providers of services (e.g., DaVita, Fresenius) that bill Medicare for dialysis services.

What happens

Creates a new billing pathway for dialysis during hospice, potentially increasing utilization of dialysis among hospice patients who previously may have forwent treatment due to coverage uncertainty.

Stock impact

DaVita operates ~2,600 dialysis centers in the US; Medicare is its largest payer. The bill expands the addressable patient population for dialysis services by removing a coverage barrier for hospice patients. However, the number of Medicare hospice patients who would elect dialysis is small relative to DaVita's total patient base, so revenue impact is marginal.

$$FMS▲ Bullish
Est. $5.0M$20.0M revenue impact

What the bill does

Same as above: clarifies Medicare coverage and separate payment for palliative dialysis during hospice.

Who must act

Fresenius Medical Care's dialysis clinics in the US.

What happens

Same as above: new billing pathway may increase dialysis utilization among hospice patients.

Stock impact

Fresenius is the largest dialysis provider globally with ~2,500 US clinics. Medicare is its primary payer. The bill provides a modest incremental revenue opportunity from a small patient subset, but the overall impact on FMS's ~$20B annual revenue is negligible.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →